Mr. Aras Azadian reports

AVICANNA ANNOUNCES APPOINTMENT OF PAUL FORNAZZARI TO BOARD OF DIRECTORS

Avicanna Inc. has appointed Paul Fornazzari to its board of directors.

Mr. Fornazzari is a business executive, securities lawyer and board director with over 25 years of experience with growth-stage and established Canadian and international companies. Mr. Fornazzari is also a partner focusing on securities and corporate finance with Fasken Martineau DuMoulin, one of Canada's largest law firms with a well-recognized domestic and international practice. In addition to English, Mr. Fornazzari is a fluent Spanish speaker from Latin America.

"I am excited to be joining the board of directors," said Mr. Fornazzari, and further said, "As a long-time shareholder, I believe in the company's management and in the company's business model, I have been excited over the company's recent developments, and I look forward to contributing towards the company's future as the Avicanna team aims and works to grow the business."

"We are thrilled to add Mr. Fornazzari to our board of directors, where his expertise and experience with successful entrepreneurial projects will support the further growth of the company," stated Aras Azadian, chief executive officer.

About Avicanna Inc.

Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform, including research and development and clinical development, that has led to the commercialization of more than 30 products across various market segments:

• Medical cannabis and wellness products (RHO Phyto): The formulary offers a diverse range of proprietary formulations including oral, sublingual, topical and transdermal deliveries with varying ratios of cannabinoids, and is supported with continuing patient and medical community education. RHO Phyto has been established as a leading medical brand in Canada, is currently available nationwide to patients across several medical channels and continues to expand into new international markets.
• Pharmaceutical preparations and pipeline: Leveraging Avicanna's scientific platform, vertical integration and real-world evidence, Avicanna has developed an extensive a pipeline of patent-pending drug candidates that are indication specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Avicanna's first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America.
• MyMedi medical cannabis care: MyMedi is Avicanna's medical cannabis care platform that is formed with the aim to better serve medical cannabis patients' needs and enhance the patient journey. MyMedi features diverse and scientifically curated products from leading Canadian licensed producers in addition to pharmacist-led patient support programs and educational resources to facilitate the incorporation of medical cannabis into health care regimens. MyMedi also provides specialty services to distinct patient groups such as veterans and collaborates with public and private providers for adjudication and reimbursement.

We seek Safe Harbor.